Business context and reporting period
The supplied filing is AntriaBio, Inc.’s unaudited Form 10-Q for the quarter ended December 31, 2015 (the second quarter of its fiscal year), not a filing identified as Rezolute, Inc. AntriaBio was a preclinical biopharmaceutical company developing sustained-release injectable products. Its lead candidate, AB101, was a once-weekly insulin formulation; AB301, a potential combination therapy, was added to its pipeline.
Financial performance and position
| Metric | Three months ended Dec. 31, 2015 | Six months ended Dec. 31, 2015 | Comparable 2014 period |
|---|---|---|---|
| Revenue | None; the company reported no revenue since inception. | ||
| Operating expenses | $4.07 million | $7.37 million | $3.07 million and $5.30 million, respectively |
| Research and development | $2.52 million | $4.49 million | $1.57 million and $1.68 million, respectively |
| General and administrative | $1.54 million | $2.87 million | $1.50 million and $3.63 million, respectively |
| Net loss | $4.07 million | $7.35 million | $2.94 million and $5.15 million, respectively |
| Net loss per common share | $0.17 | $0.30 | $0.16 and $0.28, respectively |
There was no revenue or gross profit, so operating margins are not meaningful. Six-month operating cash use was $4.80 million, versus $3.21 million a year earlier. Investing cash use was $0.62 million, including $1.26 million of fixed-asset purchases; financing provided $1.85 million, primarily from preferred stock issuance. Cash declined $3.57 million from June 30 to $1.71 million at December 31.
At December 31, current assets were $1.84 million and current liabilities $2.49 million, a $649,001 working-capital deficit. Total liabilities were $2.95 million. The balance sheet also showed $1.80 million of Series A convertible preferred stock subject to redemption and stockholders’ equity of $3.78 million. The company had $60,000 of matured convertible notes outstanding, accruing interest at 8%. Common shares outstanding were 24,338,219.
Changes versus the prior comparable period
- Six-month net loss increased to $7.35 million from $5.15 million. R&D rose substantially as staffing, research activity, and preparation for clinical-material manufacturing increased.
- Six-month G&A declined to $2.87 million from $3.63 million, which management attributed to lower consulting and investor-relations costs as functions moved in-house.
- Cash fell from $5.28 million at June 30, 2015 to $1.71 million at December 31, despite the December preferred-stock financing.
- Fixed assets increased to $6.07 million from $4.52 million as the company completed construction of its manufacturing suite.
Outlook, risks, and notable items
Management said available cash and expected operating cash flows would not sustain operations for more than one year and estimated that it needed approximately $13–$18 million to fund objectives through calendar 2016. Plans included manufacturing cGMP AB101 material, completing and filing an IND, conducting the first AB101 clinical study, and continuing AB301 preclinical work. Additional financing was not assured and could dilute shareholders or increase liabilities.
AB101’s IND and initial clinical study were delayed into 2016. Management cited FDA feedback requesting at least six months of drug-substance stability data, rather than the one month it had anticipated, as well as delays completing and certifying the cGMP suite. The company expected to file the IND near the end of the second quarter of calendar 2016, subject to progress and FDA acceptance. Six-week repeat-dose toxicology studies in dogs and rats were complete, with analysis and reports still underway. AB301 remained in preclinical development.
The filing explicitly states that substantial doubt exists about the company’s ability to continue as a going concern. It also reports ineffective disclosure controls and procedures due to a material weakness involving lack of segregation of duties and the need for a stronger control environment. The company reported no pending or threatened lawsuits expected to have a material effect, and no off-balance-sheet transactions. Lease commitments included $1.66 million of minimum rent for the principal facility through fiscal 2020, in addition to equipment-lease commitments.
Series A preferred stock issued in December carried a 6% cumulative dividend payable in shares, conversion rights at $1.95 per share subject to adjustment, and redemption provisions, including mandatory redemption after ten years or on specified events. Its liquidation preference ranked ahead of other shareholders.
Key facts for investors to verify
- Confirm the filing’s registrant: the provided text identifies AntriaBio, Inc., while the request metadata names Rezolute, Inc.
- Assess whether the company obtained the estimated $13–$18 million of funding and how financing terms affected dilution, liquidity, and preferred-stock obligations.
- Check subsequent progress on AB101 stability data, cGMP suite certification, IND submission and acceptance, and clinical-study timing; the stated dates were forward-looking expectations.
- Review the status and repayment or conversion of the matured $60,000 notes, accrued preferred dividends, and lease commitments.
- Check whether management remediated the disclosed material weakness and whether any later filing updates the going-concern assessment.